Effect of 2 Doses of EPA on Apoptosis and Cell Proliferation on Colon Mucosa
NCT00432913 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2008-10-17
Summary
The purpose of this study is to determine the effect of two doses purified EPA (an omega-3 fatty acid), on apoptosis (natural cell death) and cell proliferation (formation of new cells) in the lining of the colon for patients with a history of colonic polyps.
Conditions
- Adenomatous Polyps
Interventions
- DRUG
-
Eicosapentaenoic Acid (EPA)
Either 2 x 500mg EPA capsules in the morning and evening (2g per day EPA) or 1 x 500mg EPA and 1 x placebo in the morning and evening (1g per day EPA)
- PROCEDURE
-
Endoscopy
At baseline, month 3 and month 6.
- PROCEDURE
-
Biopsies taken
9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.
- PROCEDURE
-
Clinical chemistry
Full blood count at baseline, month 3 and month 6.
- PROCEDURE
-
Haematology
Urea and electrolytes, liver function tests, clotting profile and CRP at baseline, month 3 and month 6.
- PROCEDURE
-
Physical examination
Including cardio-respiratory and abdominal examination at baseline, month 3 and month 6.
- PROCEDURE
-
Vital signs
Height, weight, heart rate, blood pressure and temperature at baseline, month 3 and month 6.
- PROCEDURE
-
Urine pregnancy test
For subjects of child-bearing potential, urine pregnancy test at baseline, month 3 and month 6.
- PROCEDURE
-
Completion of patient diary card
Subjects are requested to complete when study medication is taken and in any new or unusual symptoms are experienced on a daily basis for 6 months.
Sponsors & Collaborators
-
S.L.A. Pharma AG
lead INDUSTRY
Principal Investigators
-
Nicholas J West, MB BS FRCS · St. George's Hospital Medical School, London
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-10-31
- Primary Completion
- 2008-06-30
- Completion
- 2008-06-30
Countries
- Italy
- United Kingdom
Study Locations
More Related Trials
-
Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients
NCT00134758 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis
NCT00319007 ·Status: UNKNOWN ·Phase: PHASE2
-
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
NCT01483144 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis
NCT05014360 ·Status: COMPLETED ·Phase: PHASE1
-
The CHAMP-study: The CHemopreventive Effect of Lithium in Familial AdenoMatous Polyposis
NCT05402891 ·Status: COMPLETED ·Phase: PHASE2
-
Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
NCT00927485 ·Status: COMPLETED ·Phase: NA
-
Cold Atmospheric Plasma for the Endoscopic Treatment of Duodenal Polyps in Patients With Familial Adenomatous Polyposis
NCT06435533 ·Status: RECRUITING ·Phase: NA
-
Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis
NCT00026468 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm
NCT01525706 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)
NCT00140894 ·Status: TERMINATED ·Phase: PHASE4
-
Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients
NCT00248053 ·Status: WITHDRAWN ·Phase: PHASE2
-
Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01
NCT04674228 ·Status: COMPLETED
-
Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding Study
NCT00285701 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)
NCT00141193 ·Status: COMPLETED ·Phase: PHASE3
-
Non-Surgical Management of Attenuated and Deleterious (Classical) Familial Adenomatous Polyposis: A Long-term Surveillance Program
NCT02747862 ·Status: COMPLETED
-
Recto Colonic Endoscopic Mucosal Resection and Polypectomy Under Clopidogrel
NCT01807169 ·Status: COMPLETED ·Phase: PHASE4
-
Does Routine Submucosal Injection Improve Complete Resection of 4-20 mm Neoplastic Colorectal Polyps?
NCT04548947 ·Status: COMPLETED ·Phase: NA
-
Tranexamic Acid to Prevent Bleeding After Endoscopic Resection of Large Colorectal Polyps: A Pilot Project
NCT04559880 ·Status: COMPLETED ·Phase: PHASE4
-
Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard Endoscopy
NCT00253812 ·Status: UNKNOWN ·Phase: NA
-
PULSed Field ablAtion of coloRectal Polyps
NCT06317727 ·Status: RECRUITING
-
Computer Assisted Optical Assessment of Small Colorectal Polyps
NCT02522702 ·Status: UNKNOWN
-
Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW
NCT02113202 ·Status: COMPLETED ·Phase: PHASE1
-
Study of QRH-882260 Heptapeptide Application in the Colon
NCT03148119 ·Status: TERMINATED ·Phase: PHASE1
-
Post-resection Treatment of Large Colon Polyps
NCT03654209 ·Status: COMPLETED ·Phase: NA
-
A Phase I In-Vivo Peptide Applied in the Right Colon
NCT01722058 ·Status: COMPLETED ·Phase: PHASE1